

CURRICULUM VITAE

Joshua J. Field MD

Professor

Department of Medicine

Division of Hematology and Oncology - Medicine

Section Chief, Benign Hematology, Medical College of Wisconsin, Milwaukee, WI

Medical Director, Adult Sickle Cell Clinic, Froedtert Hospital, Milwaukee, WI

Senior Investigator, Versiti Blood Research Institute, Versiti, Milwaukee, WI

OFFICE ADDRESS:

Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226
Phone: 414-805-4600
Fax: 414-937-6811
Email: jfield@mcw.edu

EDUCATION:

08/1992 - 08/1996 B.S., Biology, Indiana University, Bloomington, IN
08/1997 - 05/2001 M.D., Medical Doctor, University of Iowa, Iowa City, IA
08/2007 - 08/2010 M.S., Genetic Epidemiology, Washington University, St. Louis, MO

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

07/2001 - 06/2004 Resident, Internal Medicine, Washington University School of Medicine, St. Louis, MO
07/2003 - 12/2003 Chief Resident, Veterans Administration Medical Center, Washington University, St. Louis, MO
07/2004 - 06/2007 Fellow, Hematology, Washington University School of Medicine, St. Louis, MO
07/2005 - 06/2006 Fellow, Transfusion Medicine, Washington University School of Medicine, St. Louis, MO
02/2006 - 06/2007 Chief Fellow, Hematology/Oncology, Washington School of Medicine, St. Louis, MO

FACULTY APPOINTMENTS:

07/2007 - 06/2010 Instructor in Medicine, Hematology, Washington University School of Medicine, St. Louis, MO
06/2010 - 06/2013 Assistant Professor of Medicine, Medical College of Wisconsin, Milwaukee, WI
07/2010 - 06/2013 Associate Medical Director, Versiti Blood Center of Wisconsin, Milwaukee, WI
07/2010 - 07/2013 Associate Investigator, Versiti Blood Research Institute, Versiti Blood Center of Wisconsin, Milwaukee, WI
02/2012 - 06/2013 Assistant Professor of Clinical and Translational Sciences Institute, Medical College of Wisconsin, Milwaukee, WI
07/2013 - 07/2018 Associate Professor of Medicine and Clinical and Translational Sciences Institute, Medical College of Wisconsin, Milwaukee, WI
07/2013 - 07/2018 Medical Director, Versiti Blood Center of Wisconsin, Milwaukee, WI
11/2013 - 08/2019 Investigator, Versiti Blood Center of Wisconsin, Milwaukee, WI
07/2018 - 04/2022 Senior Medical Director, Versiti Blood Center of Wisconsin, Milwaukee, WI
07/2018 - Present Professor of Medicine and Clinical and Translational Sciences Institute, Medical College of Wisconsin, Milwaukee, WI
08/2019 - Present Senior Investigator, Versiti Blood Center of Wisconsin, Milwaukee, WI
04/2022 - Present Professor of Medicine, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:

07/2007 - 06/2010 Internist/Hematologist, Barnes-Jewish Hospital, 1 Barnes-Jewish Plaza, St. Louis, MO
 07/2007 - 12/2009 Associate Director of Hematology Laboratory, Washington University School of Medicine, St. Louis, MO
 09/2010 - Present Internist/Hematologist, Froedtert Lutheran Memorial Lutheran Hospital, 9200 W. Wisconsin Ave. 4th floor cancer center, 9200 W. Wisconsin Ave. 4th floor cancer center, WI 53226
 09/2010 - 09/2017 Internist/Hematologist, Children's Hospital of Wisconsin, 9000 W. Wisconsin Avenue, Milwaukee, WI 53226
 09/2011 - Present Medical Director, Adult Sickle Cell Clinic, Froedtert Hospital/Medical College of Wisconsin, 9200 W. Wisconsin Ave., WI 53226
 01/2017 - Present Section Chief, Benign Hematology, Medicine, Hematology Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Ave., WI 53226
 05/01/2021 - 03/01/2022 Interim Director, Medical Sciences Institute (Versiti physician group), Versiti Blood Center of Wisconsin, Milwaukee, WI

HOSPITAL STAFF PRIVILEGES:

09/2010 - Present Froedtert Memorial Lutheran Hospital, 9200 W. Wisconsin Ave., WI 53226
 09/2019 - Present Froedtert Menomonee Falls, N8085 Town Hall Road, Menomonee Falls, WI 53051
 09/2019 - Present Froedtert West Bend, 1700 West Paradise Drive, West Bend, WI 53095

SPECIALTY BOARDS AND CERTIFICATION:

<u>Board Certified</u>	<u>Issue Date</u>	<u>Expiration</u>
Internal Medicine	08/2004	12/2014
Hematology	10/2008	12/2028
Transfusion Medicine	09/14/2011	12/31/2021

<u>Licensure</u>	<u>Number</u>	<u>Issue Date</u>	<u>Expiration</u>
Wisconsin License	54286-20	04/01/2011	10/31/2025

AWARDS AND HONORS:

08/1996 Phi Beta Kappa, Indiana University, Bloomington, IN
 08/1996 Highest Distinction, Indiana University, Bloomington, IN
 10/2000 Alpha Omega Alpha, University of Iowa School of Medicine, Iowa City, IA
 06/2001 John & Oral Sebelin Award, Awarded to a medical student demonstrating promise in the practice of Internal Medicine , University of Iowa School of Medicine, Iowa City, IA
 10/2005 Knowlton Incentive for Excellence Award, Awarded to medicine housestaff demonstrating excellence in medical practice and patient care, Washington University School of Medicine, St. Louis, MO
 08/2007 Clinical Research Training Institute, Intensive one-year training in the methodologies of clinical research awarded to approximately 30 trainees nation-wide , American Society of Hematology
 12/2012 Health Care Hero Award, Awarded to individuals making a difference in the front lines of health care, Milwaukee Business News, Milwaukee, WI
 2012 - 2013 Medical College Outstanding Medical M1 Student Teacher, Medical College of Wisconsin, Milwaukee, WI
 06/2013 Engstrom Award for Clinical Contribution, In recognition of commitment to clinical practice, Medical College of Wisconsin, Milwaukee, WI
 08/2013 Medical College Physicians Excellence in Professionalism Award, Medical College of Wisconsin, Milwaukee, WI
 06/2017 Thomas A. Smallwood Award, Given by hospital board of directors in recognition of patient care excellence, Froedtert Hospital, Milwaukee, WI

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

01/2005 - Present American Society of Hematology (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Journal Review

2010 Blood, American Journal of Hematology
2012 Atherosclerosis, Thrombosis and Vascular Biology, British Journal of Haematology, Transfusion
2013 Pain Management Journal reviewer
2014 British Journal of Haematology, Transfusion
2015 - 2016 Blood, PlosOne
2016 New England Journal of Medicine, Science Translational Medicine, PlosOne, Brain Connectivity
2017 Reviewer for Blood, Blood Advances
2019 ASH Educational Session
2022 Blood Advances

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

01/2014 - 01/2016 American Society of Hematology: Committee on Training
01/2016 - 01/2020 American Society of Hematology: Committee on Quality
09/2016 - 09/2022 Institutional Data and Safety Monitoring External Board Chair, "A Phase IIb Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety Tolerability and Efficacy of Riociguat in Patients with Sickle Cell Diseases (STERIO-SCD), University of Pittsburgh
01/2017 - 01/2019 Chair, Acute Pain Taxonomy Project, American Pain Society/American Association of Pain Management
01/2017 - 01/2019 American Thoracic Society Committee, SCD Research Initiatives
01/2017 - 01/2019 American Society of Hematology Guidelines on Sickle Cell Disease Committee

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Peer Review

Title:	SHP655 (rADAMTS13): A Phase 1/2 randomized, double-blind, placebo-controlled, multicenter, ascending dose, safety and PK/PD study of SHP655 (rADAMTS13) in sickle cell disease at baseline health and during acute vaso-occlusive crisis
Source:	Baxalta US Inc.
Role & Effort:	Principal Investigator
PI:	Field, Joshua
Dates:	02/2020 - Present
Title:	An Adaptive, Randomized, Placebocontrolled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease
Source:	Forma Therapeutics 4202-HEM-301
Role & Effort:	Principal Investigator
PI:	Field, Joshua
Dates:	11/2021 - Present
Title:	A Phase 2a, double-blind, randomized, placebo-controlled ascending dose and maintenance dose safety and efficacy study of multiple doses of VIT-2763 in subjects with sickle cell disease
Source:	Vifor International, Ltd. VIT-2763-SCD-202
Role & Effort:	Principal Investigator
PI:	Field, Joshua

Dates: 03/2022 - Present

Pending

Peer Review

Title: "Feasibility Study of Regadenoson for the Treatment of Acute Chest Syndrome"
Source: NIH/NHLBI, R34HL108757
Role & Effort: Principal Investigator
PI: Field and Nathan
Dates: 09/01/2011 - 08/31/2013
Direct Funds: \$27,910 (Total Direct Costs: \$16,966 (Versiti) Total Indirect Costs: \$10,944 (Versiti) Total Costs: \$27,910 (Versiti))

Title: "Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia"
Source: Doris Duke Innovations in Clinical Research Award
Role & Effort: Principal Investigator
PI: Field and Lindner
Dates: 01/01/2012 - 12/31/2014
Direct Funds: \$191,563 (Total Direct Costs: \$177,374 (Versiti) Total Indirect Costs: \$14,189 (Versiti) Total Costs: \$191,563 (Versiti))

Prior

Peer Review

Title: "Clinical Hematology Research Career Development Award at Washington University (K12)"
Source: NIH
Role & Effort: Award recipient
PI: Sadler
Dates: 07/01/2007 - 06/30/2010

Title: "NHLBI Sickle Cell Disease Health-Related Quality of Life Questionnaire Development Project"

Source: NIH
Role & Effort: Institutional Investigator
PI: Werner
Dates: 07/2008 - 01/2010

Title: "A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Activity of TRF-1101 on Microvascular Blood Flow, Vascular Endothelial Injury, and Vaso-occlusive Pain in Patients with Sickle Cell Disease"

Source: TRF Pharma
Role & Effort: Institutional Investigator
PI: Embury

Dates: 10/2009 - 04/2009
 Title: "Neurophysiological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adult Patients with Sickle Cell Disease- Phase II Pilot Intervention Study"
 Source: NIH
 Role & Effort: Institutional Investigator
 PI: Vichinsky
 Dates: 01/2010 - 06/2010
 Title: "Lymphocyte Activation in Sickle Cell Lung Disease "
 Source: NIH/NHLBI, R01HL095704
 Role & Effort: Co-Investigator
 PI: Linden
 Dates: 05/01/2010 - 04/30/2015
 Direct Funds: \$145,532 (Total Direct Costs: \$88,470 (Versiti) Total Indirect Costs: \$57,062 (Versiti) Total Costs: \$145,532 (Versiti))
 Title: "Adenosine A2A Agonist Lexiscan in Children and Adults with Sickle Cell Anemia"
 Source: NIH/NHLBI, RC2HL101367
 Role & Effort: Co-Investigator
 PI: Nathan
 Dates: 09/03/2010 - 08/31/2011
 Title: "Fibrocytes in the Pathogenesis of Sickle Cell Lung Disease"
 Source: NIH/NHLBI, R01HL098526
 Role & Effort: Co-Investigator
 PI: Rose
 Dates: 09/05/2010 - 09/21/2014
 Direct Funds: \$492,756 (Total Direct Costs: \$321,182 (Versiti) Total Indirect Costs: \$168,574 (Versiti) Total Costs: \$492,756 (Versiti))
 Title: "Biomarkers of Inflammation and Vaso-Occlusion in Sickle Cell Disease"
 Source: NIH/NHLBI – 4R01HL111969-05
 Role & Effort: Principal Investigator
 PI: Field, Nathan, Linden, Ley, Lindner
 Dates: 01/01/2012 - 12/31/2016
 Direct Funds: \$570,489 (Total Direct Costs:\$341,611 (Versiti) Total Indirect Costs:\$228,878 (Versiti) Total Costs:\$570,489 (Versiti))
 Title: "A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia"
 Source: NIH/NHLBI, 4P50HL110790-05
 Role & Effort: Principal Investigator
 PI: Field, Joshua
 Dates: 07/15/2012 - 06/30/2017
 Direct Funds: \$1,210,750 (Total Direct Costs:

\$725,000 (Versiti) Total Indirect Costs:
\$485,750 (Versiti) Total Costs:
\$1,210,750 (Versiti))

Title: "A Single Ascending Dose (SAD) Phase I Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Biologic Activity of Intravenous (IV) NKTT120 in Adults with Stable Sickle Cell Disease (SCD)"
Source: NKT Therapeutics Inc.
Role & Effort: Principal Investigator
PI: Field, Joshua
Dates: 01/17/2013 - 01/16/2015

Title: "Intensive Management Protocol to Reduce Hospital Readmission in Adults with Sickle Cell Disease"
Source: CTSI, MCW
Role & Effort: Principal Investigator
PI: Field, Joshua
Dates: 07/01/2013 - 06/30/2013
Direct Funds: \$25,000

Title: "Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia"
Source: FDA, 7R01FD004117-05
Role & Effort: Principal Investigator
PI: Field and DeBaun
Dates: 09/15/2013 - 08/31/2018
Direct Funds: \$569,641 (Total Direct Costs: \$341,102 (Versiti) Total Indirect Costs: \$228,539 (Versiti) Total Costs: \$569,641 (Versiti))

Title: "Comparison of Patient Centered Outcomes in the Management of Pain between Emergency Departments and Dedicated Acute Care Facilities for Adults with Sickle Cell Disease"
Source: PCORI
Role & Effort: Co-Investigator
PI: Lanzkron
Dates: 01/01/2015 - 12/31/2018
Direct Funds: \$463,262 (Total Direct Costs: \$330,902 (Versiti) Total Indirect Costs: \$132,360 (Versiti) Total Costs: \$463,262 (Versiti))

Title: "Functional MRI of the Brain in Adults with Sickle Cell Disease"
Source: CTSI
Role & Effort: Principal Investigator
PI: Field, Joshua
Dates: 04/01/2016 - 03/31/2017
Direct Funds: \$47,500

Title: "GRNDaD: Globin Regional Network for Database and Discovery"

Source:	Doris Duke Charitable Foundation
Role & Effort:	Co-Investigator
PI:	Little
Dates:	10/01/2016 - 09/30/2017
Direct Funds:	\$25,000 (Total Direct Costs: \$23,148 (Versiti) Total Indirect Costs: \$1,852 (Versiti) Total Costs: \$25,000 (Versiti))
Title:	“A Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-occlusive Crises in the Infusion Clinic Setting: A Placebo-Controlled, Single-Dose, Double-Blind Study in Adult Sickle Cell Disease Patients”
Source:	Prolong Pharmaceuticals, Inc.
Role & Effort:	Principal Investigator
PI:	Field, Joshua
Dates:	01/01/2017 - 12/31/2018
Title:	“A Phase 1 Open-Label, Dose-Escalation/Dose-Expansion Safety and Tolerability Study of INCB059872 in Subjects with Sickle Cell Disease”
Source:	Incyte Corporation
Role & Effort:	Principal Investigator
PI:	Field, Joshua
Dates:	11/01/2017 - 08/29/2017
Title:	“A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease”
Source:	Cyclerion Pharmaceuticals, Inc.
Role & Effort:	Principal Investigator
PI:	Field, Joshua
Dates:	06/01/2018 - 06/01/2020
Title:	“Peripheral Sensitization as a Novel Mechanism for Pain in Sickle Cell Disease”
Source:	NIH/NHLBI – 5K23HL114636-05
Role & Effort:	Co-Investigator
Dates:	07/01/2018 - 05/31/2019
Direct Funds:	\$21,600 (Description: The goal of this proposal is to provide the applicant a pathway to independence as a clinical investigator and expert in the field of pain in sickle cell disease (SCD). Total Direct Costs:\$10,000 (Versiti) Total Indirect Costs:\$800 (Versiti) Total Costs:\$10,800 (Versiti))
Title:	The Inflammatory Index as a Biomarker for Pain in Patients with Sickle Cell Disease
Source:	NIH/NINDS – R01 R61NS114954

Role & Effort:	Co-Investigator
PI:	Brandow, A.
Dates:	09/01/2018 - 08/31/2023
Direct Funds:	\$36,871 (Description: This project will investigate the development and preliminary clinical validation of the inflammatory index as a biomarker for pain in patients with sickle cell disease.)
Title:	Investigating the Role of the Microbiome and Inflammation in Acute and Chronic Pain in Patients with Sickle Cell Disease
Source:	NIH/NHLBI R01HL142657
Role & Effort:	Co-Investigator
PI:	Brandow
Dates:	09/2018 - 08/2023
Direct Funds:	\$54,554 (Description: The overall goal of this project is to investigate the contribution of the immune system and microbiome to the development and maintenance of sickle cell disease pain.)
Title:	"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia"
Source:	Rigel Pharmaceuticals, Inc.
Role & Effort:	Principal Investigator
PI:	Field, Joshua
Dates:	06/01/2019 - Present
Title:	MACC/EPPIC-Net as a Hub for the HEAL Initiative EPPIC-Net
Source:	NIH/NINDS U24NS115679
Role & Effort:	Co-Investigator
PI:	Hernandez-Meier, J / Aufderheide, T.
Dates:	09/2019 - 03/2024
Direct Funds:	\$16,724 (Description: This research provides a network of locations capable of implementing biomarker studies in patients with specific pain conditions, and clinical trials to test promising treatments for pain. Establishing this research network should produce quicker results than would otherwise be.)
Title:	COVID-19 Vaccine Response in People Living with Sickle Cell Disease
Source:	American Society of Hematology
Role & Effort:	Principal Investigator
PI:	Field, Joshua
Dates:	04/2022 - 04/2024
Title:	A Phase 2, Multi-Center, Open Label, Simon Two Stage Study to Evaluate the

	Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Source:	Rigel Pharmaceuticals, Inc.
Role & Effort:	Principal Investigator
PI:	Field, Joshua
Dates:	11/22/2106 - 12/31/2018

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

National

- Field, J, "An Overview and Translational Research Relevant to Sickle Cell Lung Disease", Internal Medicine Grand Rounds, University of Virginia, 02/2009
- Field, J, Sickle Cell Disease and Asthma: two distinct diseases or part of the same process", ASH Educational Session/American Society of Hematology, New Orleans, LA, 12/2009
- Field, J, "Phase I Study of Regadenoson in Children and Adults with Sickle Cell Disease", National Symposium on Cardiopulmonary Complications of Sickle Cell Disease, Cincinnati, OH, 06/2011
- Field, J, "Novel Therapy for Sickle Cell Crises", 3rd Annual Tarrant County Sickle Cell Disease Symposium, Fort Worth, TX, 10/2011
- Field, J, "Phase I Trial of the Adenosine A2A Agonist Regadenoson in Children and Adults with Sickle Cell Anemia", Grand Rounds, Boston Children's Hospital, Harvard University School of Medicine, Boston, MA, 11/2011
- Field, J, "Phase I Trial of the Adenosine 2A Agonist Regadenoson in Children and Adults with Sickle Cell Anemia (oral presentation)", American Society of Hematology, San Diego, CA, 12/2011
- Field, J, "Phase I Study of the Adenosine 2A Agonist Regadenoson in Sickle Cell Anemia", Central Society for Clinical Research Combined Annual Meeting 2012 (CSCR & MWAFFMR), Chicago, IL, 04/2012
- Field, J, "Prophylactic Transfusions and Alloimmunization in Adults with Sickle Cell Disease", Red Cell Genotyping Symposium 2012, Washington, DC, 09/2012
- Field, J, "Effect of Adenosine A2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia", Doris Duke ICRA Sickle Cell Workshop 2012, New York City, NY, 11/2012
- Field, J, "Role of iNKT Cells in Sickle Cell Disease", Center of Excellence in Hemoglobinopathies Research, 2013, Emory/Pittsburgh/Vanderbilt, Atlanta, GA, 2013
- Field, J, "Effect of Adenosine A2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia", Doris Duke ICRA Sickle Cell Workshop 2014, New York City, NY, 09/2014
- Field, J, "Can Selectin and Invariant Natural Killer T-Cell Therapies Meet the Needs of People with Sickle Cell Disease?", American Society of Hematology 57th Annual Meeting, Orlando, FL, 12/2015
- Field, J, "Sickle Cell Disease", American Society of Hematology, Highlights of North America, Seattle, WA, Atlanta, GA, San Diego, CA, 01/2016
- Field J, "Five Lessons Learned About Long-Term Pain Management in Adults with Sickle Cell Disease", American Society of Hematology 59th Annual Meeting, Atlanta, GA, 12/2017
- Field J, "Pain in Adults with Sickle Cell Disease", NIH Sickle Cell Symposium, 2018

Regional

- Field, J, "The Role of Hpcidin in Iron Metabolism", Medicine Grand Rounds, Washington University School of Medicine, 09/2004
- Field, J, "Asthma, Inflammation and Sickle Cell Disease Severity", Medicine Grand Rounds, Washington University School of Medicine, 05/2007
- Field, J, "Update: Benign Hematology Disorder", MCW 24th Annual Update in Primary Care, Egg Harbor, WI, 10/2011
- Field, J, "Sickle Cell Disease: What You Didn't Learn In Medical School", Care Wisconsin, Madison, WI, 10/2016

Local

- Field, J, "Adult Sickle Cell Management", Medicine Grand Rounds, Froedtert Hospital, Milwaukee, WI, 02/2011
- Field, J, "Sickle Cell Disease: when they are all grown up", Department of Pediatrics Grand Rounds,

Children's Hospital of Wisconsin, Milwaukee, WI, 06/2011

Field, J, "Sickle Cell Disease Management", Department of Emergency Medicine Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 09/2011

Field, J, "Adult Sickle Cell Disease in Milwaukee: new synergies between patient care and research", Versiti Board of Directors Meeting, Versiti Blood Center of Wisconsin, Milwaukee, WI, 12/2011

Field, J, "Adult Sickle Cell Disease Management", Advanced Practice Provider Grand Rounds, Froedtert Hospital, Milwaukee, WI, 01/2012

Field, J, "Sickle Cell Disease: When they're All Grown Up", Pediatric Surgery Basic Science Lecture Series, Children's Hospital of Wisconsin, Milwaukee, WI, 02/2012

Field, J, "Management of Adults with Sickle Cell Disease at Froedtert Hospital: A new Model for Comprehensive Care", Versiti Blood Center of Wisconsin Quarterly Meeting for Transfusion Services Supervisors from Southeastern, Milwaukee, WI, Versiti Blood Center, 03/2012

Field, J, "Sickle Cell Disease: Promoting Awareness and Understanding", Community Cultural Rounds, Froedtert Hospital, Milwaukee, WI, 09/2012

Field, J, "Pregnancy in Sickle Cell Disease", E-Learning Module, Versiti Blood Center of Wisconsin, Milwaukee, WI, 11/2012

E-Learning Module, "Role of iNKT Cells in Sickle Cell Disease", VBCW Investigator's Retreat, Milwaukee, WI, 11/2013 - 11/2103

Field, J, "Role of iNKT Cells in Sickle Cell Disease", Infectious Disease Research Grand Rounds, Milwaukee, WI, 01/2014

Field, J, "Intensive Management of Adults with Sickle Cell Disease Reduces Hospital Admissions and Re-admissions", PCOR Research Seminar, Milwaukee, WI, 02/2014

Field, J, "Psychological Disorder are Highly Prevalent in Highly Utilizing Adults with Sickle Cell Disease", Clinical and Translational Science Research Seminar, Milwaukee, WI, 09/2014

Field, J, "Sickle Cell Trait", Sports Medicine Grand Rounds, Milwaukee, WI, 11/2014

Field, J, "Sickle cell disease in pregnancy", Maternal-Fetal Medicine Grand Rounds, Milwaukee, WI, 2015

Field, J, "The Opioid Addiction Crisis; Affecting Us All Where We Work and Where We Live", Schwartz Center Rounds, Froedtert & Medical College of Wisconsin, 03/2017

Field, J, "Sickle cell disease in pregnancy", Maternal-Fetal Medicine Grand Rounds, Milwaukee, WI, 2017

Field, J, "Effect of Adenosine A2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia: lessons learned", ACRP Symposium, Milwaukee, WI

MCW TEACHING ACTIVITIES:

Medical Student Education

2012 - Present Preceptor for M1 Molecules to Cells Course, Case based Discussion Lectures – Sickle Cell

Resident and Fellow Education

2011 - Present Hematology and Oncology Fellow lecture, "Management of Adult Sickle Cell Disease"

2011 - Present Internal Medicine resident lecture, "Management of Adult Sickle Cell Disease"

EXTRAMURAL TEACHING:

Medical Student Education

07/2007 - 06/2010 Washington University School of Medicine/Barnes-Jewish Hospital, St. Louis, MO, Attending Physician, Supervise medical students, residents and fellows.

09/2010 - Present Froedtert Lutheran Hospital, Milwaukee, Wisconsin, Attending Physician

2015 - 2016 Medical College of Wisconsin QuIPS (Quality Improvement and Patient Safety Pathway), Core Session lecture for M-2s and M-3s in the Quality Improvement and Patient Safety Pathway – "Sickle Cell, Chronic Illness in the Health Care system"

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:

Medical Students

2013 - 2015 Tyler Shirel, MCW Pathways, Physician Scientist, Medical College of Wisconsin

2013 Binod Dhakal, MD, Medical College of Wisconsin

2014 - Present Anisha Ndifor, MCW Pathways, Urban and Community Health, Medical College of

Wisconsin
2014 - 2017 Meenu Singh, MD, Medical College of Wisconsin
2014 - 2016 Anush Shrestha, MD, Medical College of Wisconsin
2015 - 2017 Mamaram Ceesay, MCW Pathways, Physician Scientist, Medical College of Wisconsin
2017 - Present Benjamin Gillingham, MCW Pathways, Quality, Medical College of Wisconsin
Mami Sow, Medical College of Wisconsin, ASH Minority Award Recipient

Clinical/Research Fellows

2015 Rekha Chandran, MD, Medical College of Wisconsin
2015 Zeeshan Jawa, MD, Medical College of Wisconsin
2023 Jennifer Obasi, Medical College of Wisconsin

Residents

2013 - Present Arun Singavi, MD, Research mentor for American Society of Hematology HONORS, Medical College of Wisconsin, Hematology Opportunities for the Next Generation of Research Scientists Award
2014 - 2015 Shibani Dogra, MD, Medical College of Wisconsin
2014 - 2015 Rena Shah, MD, Medical College of Wisconsin

**EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS
MENTORED:**

Undergraduate Students

2006 - 2007 James Krings, Washington University School of Medicine
2008 - 2011 Jessica Knight-Perry, Doris Duke Clinical Research Fellowship, Washington University School of Medicine
2014 - 2016 Collin Hubbler, Versiti Blood Center of Wisconsin

Faculty

2013 - 2021 Matthew Karafin, MD, MS, Versiti Wisconsin/MCW, CTSI and an NHLBI K23 award

ABSTRACT/MANUSCRIPT/GRANT REVIEWER:

2006 American Society of Hematology Conference Abstract Reviewer: Sickle Cell Section
12/2011 Medical College of Wisconsin, CTSI Pilot Grant, Reviewer
12/2011 Symposium on Hemostasis, Special Focus on Tissue Factor, Factor VIIa, and Tissue Factor Pathway Inhibitor- Hemostasis and Beyond. Chapel Hill, NC
2011 National Heart, Lung and Blood Institute, Invited reviewer: Special Emphasis Panel BABY HUG study
02/2012 6th Annual Sickle Cell Disease Research and Educational Symposium and Annual National Sickle Cell Disease Scientific Meeting
07/2013 Doris Duke Foundation, Invited reviewer: Innovations in Clinical Research Award Competition
2014 MCW Cancer Center Seed Grant Review Committee
2014 MCW KL2 Grant Review Committee
2015 - 2016 National Heart, Lung and Blood Institute, Ad hoc reviewer: Clinical Trials Review Committee Study Section
03/2016 American Society of Hematology Research Training Award for Fellows (RTAF) Committee
2016 National Heart, Lung and Blood Institute, Chair, Invited Reviewer: Special Emphasis Panel Zika Virus
2016 NHLBI RFA, "Sickle Cell Disease Implementation Consortium (SCDIC): Using Implementation Science to Optimize Care of Adolescents and Adults with Sickle Cell Disease (U01)" Special Emphasis Panel
2016 American Society of Hematology Conference Abstract Reviewer: Sickle Cell Section
2018 National Heart, Lung and Blood Institute, Ad hoc reviewer: K01 Diversity Review
2022 National Heart, Lung and Blood Institute, Ad hoc reviewer: R33
2023 National Heart, Lung and Blood Institute, Ad hoc reviewer: P01

INVESTIGATIONAL NEW DRUG:

#114085, "Effects of the Adenosine 2A Receptor Agonist Regadenoson on Sickle Cell Vaso-occlusion and

Inflammation.” •JJ Field holds an investigational new drug number to examine regadenoson in sickle cell vaso-occlusion

PROGRAMATIC DEVELOPMENTS:

09/2011 Adult Sickle Cell Clinic, Froedtert Hospital, Milwaukee, WI • Developed first-of-kind Adult Sickle Cell Clinic in the state of Wisconsin serving 500 adults with sickle cell disease o Proposed new model for Adult Sickle Cell Clinic to administration at Medical College of Wisconsin and Froedtert Hospital to provide intensive outpatient management and coordinated care in the inpatient and emergency department setting o Created business plan with Medical College and Froedtert Hospital administration o Unique services in the Adult Sickle Cell Clinic include: ? Chronic pain management ? Acute sickle cell day hospital for infusions ? Hydroxyurea management ? Transfusion therapy ? Sickle cell providers rounding daily on inpatients and communication with inpatient staff ? Regular communication with the emergency department ? Patient care plans ? Access to state-of-the-art research studies o Currently staffed by Joshua Field, MD, MS (Medical Director), Kathryn Koch, APNP, Amy Mager, PA-C, Cynthia Leonard, RN, MSN, Vanessa Lee, RN, Aton Garth, RN.

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Field JJ, Mason PJ, An P, Kasai Y, McLellan M, Jaeger S, Barnes YJ, King AA, Bessler M, Wilson DB. Low frequency of telomerase RNA mutations among children with aplastic anemia or myelodysplastic syndrome. *J Pediatr Hematol Oncol*. 2006 Jul;28(7):450-3.
2. Field JJ, Giannone L, Bessler M, Blinder MA. Immunosuppressive therapy for acute porphyria: safety and efficacy in a patient with bone marrow failure. *Pharmacotherapy*. 2006 Nov;26(11):1662-6.
3. Field JJ, Fenske TS, Blinder MA. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. *Haemophilia*. 2007 Jan;13(1):46-50.
4. Du HY, Pumbo E, Manley P, Field JJ, Bayliss SJ, Wilson DB, Mason PJ, Bessler M. Complex inheritance pattern of dyskeratosis congenita in two families with 2 different mutations in the telomerase reverse transcriptase gene. *Blood*. 2008 Feb 01;111(3):1128-30. PMID: PMC2214749
5. Field JJ, Glassberg J, Gilmore A, Howard J, Patankar S, Yan Y, Davies SC, Debaun MR, Strunk RC. Longitudinal analysis of pulmonary function in adults with sickle cell disease. *Am J Hematol*. 2008 Jul;83(7):574-6. PMID: PMC3729267
6. Field JJ, Austin PF, An P, Yan Y, DeBaun MR. Enuresis is a common and persistent problem among children and young adults with sickle cell anemia. *Urology*. 2008 Jul;72(1):81-4. PMID: PMC3729268
7. Jennings JE, Ramkumar T, Mao J, Boyd J, Castro M, Field JJ, Strunk RC, DeBaun MR. Elevated urinary leukotriene E4 levels are associated with hospitalization for pain in children with sickle cell disease. *Am J Hematol*. 2008 Aug;83(8):640-3. PMID: PMC3729258
8. Field JJ, DeBaun MR, Yan Y, Strunk RC. Growth of lung function in children with sickle cell anemia. *Pediatr Pulmonol*. 2008 Nov;43(11):1061-1066.
9. Strunk RC, Brown MS, Boyd JH, Bates P, Field JJ, DeBaun MR. Methacholine challenge in children with sickle cell disease: a case series. *Pediatr Pulmonol*. 2008 Sep;43(9):924-9. PMID: PMC3722869
10. Field JJ, Macklin EA, Yan Y, Strunk RC, DeBaun MR. Sibling history of asthma is a risk factor for pain in children with sickle cell anemia. *Am J Hematol*. 2008 Nov;83(11):855-7. PMID: PMC2590666
11. Frei-Jones MJ, Field JJ, DeBaun MR. Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease. *Pediatr Blood Cancer*. 2009 Apr;52(4):481-5. PMID: PMC2730199
12. Field JJ, Krings J, White NL, Yan Y, Blinder MA, Strunk RC, Debaun MR. Urinary cysteinyl leukotriene E(4) is associated with increased risk for pain and acute chest syndrome in adults with sickle cell disease. *Am J Hematol*. 2009 Mar;84(3):158-60.
13. Field JJ, Strunk RC, Knight-Perry JE, Blinder MA, Townsend RR, DeBaun MR. Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease. *Am J Hematol*. 2009 Apr;84(4):231-3.
14. Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. *Am J Hematol*. 2009 Jul;84(7):418-21.
15. Knight-Perry JE, Field JJ, Debaun MR, Stocks J, Kirkby J, Strunk RC. Hospital admission for acute painful episode following methacholine challenge in an adolescent with sickle cell disease. *Pediatr Pulmonol*.

- 2009 Jul;44(7):728-30. PMID: PMC3729266
16. Frei-Jones MJ, Field JJ, DeBaun MR. Multi-modal intervention and prospective implementation of standardized sickle cell pain admission orders reduces 30-day readmission rate. *Pediatr Blood Cancer*. 2009 Sep;53(3):401-5. PMID: PMC2722244
 17. Wallace KL, Marshall MA, Ramos SI, Lannigan JA, Field JJ, Strieter RM, Linden J. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. *Blood*. 2009 Jul 16;114(3):667-76. PMID: PMC2713467
 18. Cohen RT, DeBaun MR, Blinder MA, Strunk RC, Field JJ. Smoking is associated with an increased risk of acute chest syndrome and pain among adults with sickle cell disease. *Blood*. 2010 May 06;115(18):3852-4. PMID: PMC2915907
 19. Polanowska-Grabowska R, Wallace K, Field JJ, Chen L, Marshall MA, Figler R, Gear AR, Linden J. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. *Arterioscler Thromb Vasc Biol*. 2010 Dec;30(12):2392-9. PMID: PMC3058044
 20. Field JJ, Stocks J, Kirkham FJ, Rosen CL, Dietzen DJ, Semon T, Kirkby J, Bates P, Seicean S, DeBaun MR, Redline S, Strunk RC. Airway hyperresponsiveness in children with sickle cell anemia. *Chest*. 2011 Mar;139(3):563-568. PMID: PMC3047289
 21. Field JJ, Horst J, Strunk RC, White FV, DeBaun MR. Death due to asthma in two adolescents with sickle cell disease. *Pediatr Blood Cancer*. 2011 Mar;56(3):454-7.
 22. Cohen RT, Madadi A, Blinder MA, DeBaun MR, Strunk RC, Field JJ. Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease. *Am J Hematol*. 2011 Sep;86(9):756-61. PMID: PMC4103016
 23. Knight-Perry JE, de las Fuentes L, Waggoner AD, Hoffmann RG, Blinder MA, Dávila-Román VG, Field JJ. Abnormalities in cardiac structure and function in adults with sickle cell disease are not associated with pulmonary hypertension. *J Am Soc Echocardiogr*. 2011 Nov;24(11):1285-90. PMID: PMC3200507
 24. Field JJ, Burdick MD, DeBaun MR, Strieter BA, Liu L, Mehrad B, Rose CE Jr, Linden J, Strieter RM. The role of fibrocytes in sickle cell lung disease. *PLoS One*. 2012;7(3):e33702. PMID: PMC3307761
 25. Keeley EC, Mehrad B, Janardhanan R, Salerno M, Hunter JR, Burdick MM, Field JJ, Strieter RM, Kramer CM. Elevated circulating fibrocyte levels in patients with hypertensive heart disease. *J Hypertens*. 2012 Sep;30(9):1856-61. PMID: PMC3643814
 26. Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto F, Neuberger D, Linden J, Nathan DG. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. *Blood*. 2013 Apr 25;121(17):3329-34. PMID: PMC3637009
 27. Cohen RT, Strunk RC, Field JJ, Rosen CL, Kirkham FJ, Redline S, Stocks J, Rodeghier MJ, DeBaun MR. Environmental tobacco smoke and airway obstruction in children with sickle cell anemia. *Chest*. 2013 Oct;144(4):1323-1329. PMID: PMC3787918
 28. Blinder MA, Geng B, Lisker-Melman M, Crippin JS, Korenblat K, Chapman W, Shenoy S, Field JJ. Successful orthotopic liver transplantation in an adult patient with sickle cell disease and review of the literature. *Hematol Rep*. 2013 Jan 25;5(1):1-4. PMID: PMC3719104
 29. Lin G, Field JJ, Yu JC, Ken R, Neuberger D, Nathan DG, Linden J. NF- κ B is activated in CD4+ iNKT cells by sickle cell disease and mediates rapid induction of adenosine A2A receptors. *PLoS One*. 2013;8(10):e74664. PMID: PMC3790763
 30. Koch KL, Karafin MS, Simpson P, Field JJ. Intensive management of high-utilizing adults with sickle cell disease lowers admissions. *Am J Hematol*. 2015 Mar;90(3):215-9.
 31. Shrestha A, Jawa Z, Koch KL, Rankin AB, Xiang Q, Padmanabhan A, Karafin MS, Field JJ. Use of a dual lumen port for automated red cell exchange in adults with sickle cell disease. *J Clin Apher*. 2015 Dec;30(6):353-8.
 32. Karafin MS, Field JJ, Gottschall JL, Denomme GA. Barriers to using molecularly typed minority red blood cell donors in support of chronically transfused adult patients with sickle cell disease. *Transfusion*. 2015 Jun;55(6 Pt 2):1399-406.
 33. Karafin MS, Sachais BS, Connelly-Smith L, Field JJ, Linenberger ML, Padmanabhan A. NHLBI state of the science symposium in therapeutic apheresis: Knowledge gaps and research opportunities in the area of hematology-oncology. *J Clin Apher*. 2016 Feb;31(1):38-47.
 34. Karafin MS, Dogra S, Rodeghier M, Burdick M, Mehrad B, Rose CE, Strieter RM, DeBaun MR, Strunk RC, Field JJ. Increased circulating fibrocytes are associated with higher reticulocyte percent in children with sickle cell anemia. *Pediatr Pulmonol*. 2016 Mar;51(3):295-9. PMID: PMC5559871

35. Karafin MS, Koch KL, Rankin AB, Nischik D, Rahhal G, Simpson P, Field JJ. Erythropoietic drive is the strongest predictor of hepcidin level in adults with sickle cell disease. *Blood Cells Mol Dis*. 2015 Dec;55(4):304-7. PMID: PMC4754107
36. Karafin MS, Singavi AK, Irani MS, Puca KE, Baumann Kreuziger L, Simpson P, Field JJ. Red cell storage age policy for patients with sickle cell disease: A survey of transfusion service directors in the United States. *Transfus Apher Sci*. 2016 Feb;54(1):158-62.
37. Shirel T, Hubler CP, Shah R, Mager AB, Koch KL, Sheth D, Uhing MR, Jones CW, Field JJ. Maternal opioid dose is associated with neonatal abstinence syndrome in children born to women with sickle cell disease. *Am J Hematol*. 2016 Jun;91(4):416-9.
38. Karafin MS, Singavi A, Johnson ST, Field JJ. A Fatal Case of Immune Hyperhemolysis with Bone Marrow Necrosis in a Patient with Sickle Cell Disease. *Hematol Rep*. 2017 Feb 23;9(1):6934. PMID: PMC5337824
39. Belcik JT, Davidson BP, Xie A, Wu MD, Yadava M, Qi Y, Liang S, Chon CR, Ammi AY, Field J, Harmann L, Chilian WM, Linden J, Lindner JR. Augmentation of Muscle Blood Flow by Ultrasound Cavitation Is Mediated by ATP and Purinergic Signaling. *Circulation*. 2017 Mar 28;135(13):1240-1252. PMID: PMC5373943
40. Field JJ, Majerus E, Ataga KI, Vichinsky EP, Schaub R, Mashal R, Nathan DG. NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease. *PLoS One*. 2017;12(2):e0171067. PMID: PMC5289534
41. Karafin MS, Carpenter E, Pan A, Simpson P, Field JJ. Older red cell units are associated with an increased incidence of infection in chronically transfused adults with sickle cell disease. *Transfus Apher Sci*. 2017 Jun;56(3):345-351.
42. Mager A, Pelot K, Koch K, Miller L, Hubler C, Ndifor A, Coan C, Leonard C, Field JJ. Opioid management strategy decreases admissions in high-utilizing adults with sickle cell disease. *J Opioid Manag*. 2017;13(3):143-156.
43. Willen SM, Rodeghier M, Strunk RC, Rosen CL, Kirkham FJ, Field JJ, DeBaun MR, Cohen RT. Airway Hyperresponsiveness Does Not Predict Morbidity in Children with Sickle Cell Anemia. *Am J Respir Crit Care Med*. 2017 Jun 01;195(11):1533-1534. PMID: PMC5470752
44. Field JJ, Majerus E, Gordeuk VR, Gowhari M, Hoppe C, Heeney MM, Achebe M, George A, Chu H, Sheehan B, Puligandla M, Neuberg D, Lin G, Linden J, Nathan DG. Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. *Blood Adv*. 2017 Sep 12;1(20):1645-1649. PMID: PMC5728341
45. Mehrad B, Burdick MD, Wandersee NJ, Shahir KS, Zhang L, Simpson PM, Strieter RM, Field JJ. Circulating fibrocytes as biomarkers of impaired lung function in adults with sickle cell disease. *Blood Adv*. 2017 Nov 14;1(24):2217-2224. PMID: PMC5737132
46. Karafin MS, Singh M, Ceesay M, Koduri S, Zhang L, Simpson P, Field JJ. Dyspareunia is associated with chronic pain in premenopausal women with sickle cell disease. *Hematology*. 2018 Sep;23(8):531-536.
47. Karafin MS, Singavi A, Hussain J, Wandersee N, Heinrich T, Hurley RW, Zhang L, Simpson P, Field JJ. Predictive factors of daily opioid use and quality of life in adults with sickle cell disease. *Hematology*. 2018 Dec;23(10):856-863.
48. Yu JC, Lin G, Field JJ, Linden J. Induction of antiinflammatory purinergic signaling in activated human iNKT cells. *JCI Insight*. 2018 Sep 06;3(17). PMID: PMC6171811
49. Karafin MS, Fu X, D'Alessandro A, Thomas T, Hod EA, Zimring JC, Field JJ, Francis RO. The clinical impact of glucose-6-phosphate dehydrogenase deficiency in patients with sickle cell disease. *Curr Opin Hematol*. 2018 Nov;25(6):494-499.
50. Field JJ, Ballas SK, Campbell CM, Crosby LE, Dampier C, Darbari DS, McClish DK, Smith WR, Zempsky WT. AAAPT Diagnostic Criteria for Acute Sickle Cell Disease Pain. *J Pain*. 2019 Jul;20(7):746-759.
51. Lanzkron S, Little J, Field J, Shows JR, Wang H, Seufert R, Brooks J, Varadhan R, Haywood C Jr, Saheed M, Huang CY, Griffin B, Frymark S, Piehet A, Robertson D, Proudford M, Kincaid A, Green C, Burgess L, Wallace M, Segal J. Increased acute care utilization in a prospective cohort of adults with sickle cell disease. *Blood Adv*. 2018 Sep 25;2(18):2412-2417. PMID: PMC6156885
52. Karafin MS, Chen G, Wandersee NJ, Brandow AM, Hurley RW, Simpson P, Ward D, Li SJ, Field JJ. Chronic pain in adults with sickle cell disease is associated with alterations in functional connectivity of the brain. *PLoS One*. 2019;14(5):e0216994. PMID: PMC6527293
53. Karafin MS, Mullins DE, Johnson ST, Nischik D, Feng M, Simpson P, Field JJ. Chronic pain persists in adults with sickle cell disease despite regular red cell transfusions. *Transfus Apher Sci*. 2019 Aug;58(4):434-438.

54. Lindner JR, Belcik T, Widlansky M, Harmann LM, Karafin MS, Wandersee NJ, Puligandla M, Neuberg D, Linden J, Field JJ. Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease. *PLoS One*. 2019;14(7):e0218783. PMID: PMC6611596
55. Wright N, Voshtina E, George G, Singavi A, Field J. Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL). *Int J Hematol*. 2019 Dec;110(6):751-755.
56. Chou ST, Alsawas M, Fasano RM, Field JJ, Hendrickson JE, Howard J, Kameka M, Kwiatkowski JL, Pirenne F, Shi PA, Stowell SR, Thein SL, Westhoff CM, Wong TE, Akl EA. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. *Blood Adv*. 2020 Jan 28;4(2):327-355. PMID: PMC6988392
57. Clayton-Jones D, Matthie N, Treadwell M, Field JJ, Mager A, Sawdy R, George Dalmida S, Leonard C, Koch KL, Haglund K. Social and Psychological Factors Associated With Health Care Transition for Young Adults Living With Sickle Cell Disease. *J Transcult Nurs*. 2021 Jan;32(1):21-29.
58. Ruhl AP, Sadreameli SC, Allen JL, Bennett DP, Campbell AD, Coates TD, Diallo DA, Field JJ, Fiorino EK, Gladwin MT, Glassberg JA, Gordeuk VR, Graham LM, Greenough A, Howard J, Kato GJ, Knight-Madden J, Kopp BT, Koumbourlis AC, Lanzkron SM, Liem RI, Machado RF, Mehari A, Morris CR, Ogunlesi FO, Rosen CL, Smith-Whitley K, Tauber D, Terry N, Thein SL, Vichinsky E, Weir NA, Cohen RT, Klings ES. Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. *Ann Am Thorac Soc*. 2019 Sep;16(9):e17-e32. PMID: PMC6812163
59. Karafin MS, Simpson P, Field JJ. Chronic Pain Does Not Impact Baseline Circulating Cytokine Levels in Adults with Sickle Cell Disease. *Acta Haematol*. 2021;144(1):111-116.
60. Field JJ, Kassim A, Brandow A, Embury SH, Matsui N, Wilkerson K, Bryant V, Zhang L, Simpson P, DeBaun MR. Phase 2 trial of montelukast for prevention of pain in sickle cell disease. *Blood Adv*. 2020 Mar 24;4(6):1159-1165. PMID: PMC7094028
61. Lanzkron S, Little J, Wang H, Field JJ, Shows JR, Haywood C Jr, Saheed M, Proudford M, Robertson D, Kincaid A, Burgess L, Green C, Seufert R, Brooks J, Piehet A, Griffin B, Arnold N, Frymark S, Wallace M, Abu Al Hamayel N, Huang CY, Segal JB, Varadhan R. Treatment of Acute Pain in Adults With Sickle Cell Disease in an Infusion Center Versus the Emergency Department : A Multicenter Prospective Cohort Study. *Ann Intern Med*. 2021 Sep;174(9):1207-1213.
62. Wilson SR, Sears M, Williams E, Drapekin J, Sivakumar I, Padrino S, Desai PC, Hager W, Manwani D, Clay LJ, Field JJ, Kanter J, Cohen AJ, Saif Ur Rehman S, Lanzkron S, Little JA, GRNDaD investigators. Gaps in the diagnosis and management of iron overload in sickle cell disease: a 'real-world' report from the GRNDaD registry. *Br J Haematol*. 2021 Dec;195(5):e157-e160.
63. Kuter DJ, Rogers KA, Boxer MA, Choi M, Agajanian R, Arnold DM, Broome CM, Field JJ, Murakhovskaya I, Numerof R, Tong S. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study. *Am J Hematol*. 2022 Jun 01;97(6):691-699. PMID: PMC9313871
64. Karafin MS, Field JJ, Ilich A, Li L, Qaquish BF, Shevkopyas SS, Yoshida T. Hypoxic storage of donor red cells preserves deformability after exposure to plasma from adults with sickle cell disease. *Transfusion*. 2023 Jan;63(1):193-202.
65. Mucalo L, Field JJ, Highland J, Khan H, Hankins JS, Singh A, Brandow AM. Preliminary construct validity of patient-reported outcomes to assess chronic pain in adults with sickle cell disease. *Blood Adv*. 2023 Jul 25;7(14):3658-3665. PMID: PMC10365933
66. Eapen M, Brazauskas R, Williams DA, Walters MC, St Martin A, Jacobs BL, Antin JH, Bona K, Chaudhury S, Coleman-Cowger VH, DiFronzo NL, Esrick EB, Field JJ, Fitzhugh CD, Kanter J, Kapoor N, Kohn DB, Krishnamurti L, London WB, Pulsipher MA, Talib S, Thompson AA, Waller EK, Wun T, Horowitz MM. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. *J Clin Oncol*. 2023 Apr 20;41(12):2227-2237. PMID: PMC10448940
67. Goers T, Panepinto J, Blinder M, DeBaun M, Foglia R, Field JJ. Laparoscopic Abdominal Surgery in Children with Sickle Cell Disease is Associated with a Shorter Hospital Stay and Similar Rate of Post-Operative Sickle Cell Disease Complications. *Pediatric Blood & Cancer*, 2008 Mar; 5(3): 603-6.
68. Odackal J, Yu V, Gomez-Manjerres D, Field JJ, Burdick MD, Mehrad B. Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease. *ERJ Open Res*. 2020 Oct;6(4). PMID: PMC7682700
69. Singh, A, Sontag MK, Zhou M, Dasgupta M, Crume T, McLemore M, Galadanci N, Randall E, Steiner N, Brandow AM, Koch K, Field JJ, Hassell K, Snyder AB, Kanter J. Evaluating the Sickle Cell Data Collection Program's Administrative Case Definition for Adults with Sickle Cell Disease, *JMIR*,

accepted.

70. DeBaun MR, Jennings JE, Boyd JH, Field JJ, Hillery C, Strunk RC. The contribution of asthma to sickle cell disease related morbidity and mortality. 2007, Hematology Education: the education program for the annual congress of the European Hematology Association: 140-147.
71. DeBaun MR and Field JJ. Limitations of clinical trials in sickle cell disease: a case study of the multi-center study of hydroxyurea trial (MSH) and the stroke prevention trial (STOP). ASH Educational Session, 2007, American Society of Hematology Educational Program, 2007: 482-488.
72. Field JJ, Knight-Perry J, DeBaun MR. Acute pain in children and adults with sickle cell disease: management in the absence of evidence-based guidelines. *Current Opinion in Hematology*, 2009 16:173-178.
73. Knight-Perry J, DeBaun MR, Strunk RC, Field JJ. The leukotriene pathway in sickle cell disease: a potential target for directed therapy. *Expert Review in Hematology*, 2009 2(1):57-68.
74. Field JJ, Strieter R, Linden J. Sickle cell disease: an overview and translational research relevant to sickle cell lung disease. *University of Virginia Journal of Medicine*, 2009 Dec; 6:21-30.
75. Field JJ, DeBaun MR, Vichinsky E. "Overview of the management of sickle cell disease." In: Schrier S, Mahoney D (eds.) *UpToDate*: 2009.
76. Field JJ, Vemulakonda VM, DeBaun MR. "Diagnosis and management of priapism in sickle cell disease." In: Schrier S, Mahoney D (eds.) *UpToDate*: 2009.
77. Field JJ and DeBaun MR. Asthma and sickle cell disease: two distinct processes or part of the same process? ASH Educational Session, 2009, American Society of Hematology Educational Program 2009: 45-53.
78. Field JJ, Nathan DG, Linden J. Targeting iNKT cells for the treatment of sickle cell disease. *Clinical Immunology* 2011, 140(2): 177-83.
79. Field JJ, DeBaun MR. "Acute chest syndrome in adults with sickle cell disease." In: Schrier S, Mahoney D (eds.) *UpToDate*: 2012.
80. Nathan DG, Field JJ, Lin G, Neuberger D, Majerus E, Onyekwere O, Keefer J, Okam M, Ross A, Linden J. Sickle cell disease (SCD), iNKT cells, and regadenoson infusion. *Transactions of the American Clinical Climatological Association*, 2012; 123: 312 – 317.
81. Field JJ, Nathan DG, Linden J. The role of adenosine signaling in sickle cell therapeutics. *Hematology Oncology Clinics of North America*. 2014 Apr;28(2): 287-99.
82. Field JJ. Sickle cell disease: new treatments and their rationale. *Clinical Advances in Hematology Oncology*. 2013;11(11):740-743.
83. Field JJ, Nathan DG. Advances in sickle cell therapies in the hydroxyurea era. *Molecular Medicine*. 2014 Dec 16;20 Suppl 1:S37-42.
84. Field, JJ. Can Selectin and iNKT cell therapies meet the needs of people with sickle cell disease? ASH Educational Session, 2015, American Society of Hematology Educational Program 2015; 426-32.
85. Tubman V, Field JJ. Sickle solubility test: what's the harm? *American Society of Hematology Educational Program* 2015; 433-35.
86. Field JJ. Five Lessons Learned About Long-Term Pain Management in Adults with Sickle Cell Disease. ASH Educational Session, 2017, American Society of Hematology Educational Program 2017; (1):406-411.
87. Karafin MS and Field JJ. The controversial role of red cell transfusions for sickle cell pain. *Curr Opin Hematol* 2019 Nov;26(6):442-447 PMID: 31567433 SCOPUS ID: 2-s2.0-85072300896 10/01/2019
88. Singh A, Brousseau DC, Dasgupta M, Shet AS, Field JJ, Brandow AM. Acute care utilization among individuals with sickle cell disease and related cardiopulmonary and renal complications. *PLoS One*. 2024;19(4):e0297469. PMID: PMC11020686
89. Gunderson SJ, Snowden N, Field JJ. Embryo Cryopreservation in a Patient with Sickle Cell Disease Utilizing Letrozole and Enoxaparin: A Case Report. *Hematol Rep*. 2023 Feb 03;15(1):101-107. PMID: PMC9944850

Books, Chapters, and Reviews

1. Field JJ. "Renal disease in pregnancy". In: Agha I, Green G (eds.) *Washington Manual Nephrology Subspecialty Consult*, Lippincott Williams & Wilkins, 2003.
2. Field JJ, Blinder M. "Anemia and transfusion therapy". In: Cooper D, Kranik A, Lubner S, Reno H (eds.) *Washington Manual of Medical Therapeutics*, Lippincott Williams & Williams, 2007.
3. Field JJ, Lublin D, Depostis G. "Blood transfusion in the practice of oncology." In: Govindan R (ed.) *Washington Manual of Oncology, Second Edition*, Lippincott Williams & Williams: 2007.
4. Field JJ. "Renal disease in pregnancy". In: Agha I, Green G (eds.) *Washington Manual Nephrology*

- Subspecialty Consult, Lippincott Williams & Wilkins, 2003.
5. Field JJ, Blinder M. "Anemia and transfusion therapy". In: Cooper D, Kranik A, Lubner S, Reno H (eds.) Washington Manual of Medical Therapeutics, Lippincott Williams & Williams, 2007.
 6. Field JJ, Lublin D, Depostis G. "Blood transfusion in the practice of oncology." In: Govindan R (ed.) Washington Manual of Oncology, Second Edition, Lippincott Williams & Williams: 2007.

Editorials, Letters To Editor, Other

1. Field JJ, Austin P, Kemp J. Author Reply: Enuresis is a common and persistent problem among children and young adults with sickle cell anemia. *Urology*, 2008 Sep; 72(3): 720-721.
2. Field JJ, Madadi A, Siegel M, Narra V. Author Reply: Pulmonary thrombi are not detected by 3D magnetic resonance angiography in adults with sickle cell anemia and an elevated tricuspid regurgitant jet velocity. *American Journal of Hematology*, 2010; 85(3): 217-218.
3. Mast AE and Field JJ. Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome. *Transfusion*, 2012; 52(10): 2078-80.
4. Dhakal B, Giese K, Santo-Thomas L, Field JJ. Death during an asthma exacerbation in an adult with sickle cell disease: An autopsy case study. *American Journal of Hematology*, 2009; 84(10): 686-8.
5. Chandran R, Moran A, Barash M, Hopper B, Rankin A, Field JJ. A case of acute chest syndrome complicated by diffuse, cerebral infarcts in an adult with HbS⁺-thalassemia. *American Journal of Hematology*, 2015; 20.

Abstracts

1. Field JJ, Mason P, Barnes Y, King A, Bessler M, Wilson D. Mutations in the RNA component of telomerase, TERC, in children with aplastic anemia and myelodysplastic Syndrome: An NMDP Study. *American Society of Hematology Annual 47th Meeting, Atlanta, GA, 2005.*
2. Field JJ, Fenske T, Blinder M. Rituximab for the treatment of high-titer acquired factor VIII inhibitors refractory to conventional chemotherapy. *American Society of Hematology 47th Annual Meeting, Atlanta, GA, 2005.*
3. Gandhi M, Field JJ, Blinder M, Lublin D. Sickle cell hyperhemolysis syndrome: experience at one large academic medical center. *American Association of Blood Banks Annual Meeting, Miami, FL, 2006.*
4. Strouse J, Field JJ, Lanzkron S. Risk factors for hemorrhagic stroke in adults with sickle cell disease. *American Society of Hematology 49th Annual Meeting, Atlanta, GA, 2007.*
5. Strouse J, Field JJ, Crawford R, Lanzkron S. Antecedent transfusion and primary hemorrhagic stroke in adults with sickle cell disease. *American Society of Hematology 49th Annual Meeting, San Francisco, CA, 2008.*
6. Burdick MD, Mehrad B, Field JJ, DeBaun MR, Wallace K, Liu L, Strieter BA, Linden J, Strieter RM. Fibrocytes in the pathogenesis of chronic sickle lung disease. *American Thoracic Society Annual Meeting, Toronto, Ontario, 2008.*
7. Cohen R, Madadi A, Blinder MA, DeBaun MR, Strunk RC, Field JJ. Wheezing is associated with increased rates of pain and acute chest syndrome episodes in adults with sickle cell disease. *American Society of Hematology 51st Annual Meeting, Orlando, FL, 2010.*
8. Guo YH, Foster T, Field JJ, Scott JP, Wandersee NJ, Hillery CA. Low molecular weight heparin reduces sVCAM 1 and lung congestion in a murine model of sickle cell disease. *American Society of Hematology 51st Annual Meeting, Orlando, FL, 2010.*
9. Vichinsky EP, Neumayr LD, Weiner MW, Gold JI, Kasten J, Truran D, Synder C, Kesler K, Hussein A, Harrington T, McMahon L, Gordeuk V, Kutlar A, Orringer E, De Castro L, Field JJ, Swerdlow P, Bessman J, Synder R, Strouse J, Armstrong FD. The safety and efficacy of a randomized trial of transfusion vs. standard care in the prevention of sickle cell-related complications in adults: a preliminary report from the phase II neuropsychological adult sickle cell anemia study group. *American Society of Hematology 51st Annual Meeting, Orlando, FL, 2010.*
10. Field JJ, Lin G, Okam M, Majerus E, Onyekwere O, Ross A, Neuberg D, Nathan DG, Linden J. Regadenoson, an adenosine 2A receptor agonist, is safe and inhibits invariant NKT cells in sickle cell disease. *American Society of Hematology 52st Annual Meeting, San Diego, CA, 2011. [Oral presentation]*
11. Linden J, Lin G, Yu J, Neuberg D, Nathan D, Field JJ. NF- γ B activation mediates induction of anti-inflammatory adenosine A2A receptors in iNKT cells of sickle cell patients during vaso-occlusive episodes and upon activation of cultured human iNKT cells. *American Society of Hematology 55th Annual Meeting, New Orleans, LA, 2013.*

12. Lin G, Yu J, Field JJ, Nathan D, Linden J. Human sickle cell disease increases numbers and activation of peripheral blood myeloid dendritic cells, monocytes, and neutrophils. American Society of Hematology 55th Annual Meeting, New Orleans, LA, 2013.
13. Field JJ, Ataga KI, Majerus E, Eaton CA, Mashal R, Nathan DG. A phase I single ascending dose study of NKTT120 in stable adult sickle cell patients. American Society of Hematology 55th Annual Meeting. New Orleans, LA, 2013.
14. Yu J, Lin G, Ken R, Field JJ, Linden J. The role of NF- κ B in the activation of human iNKT cells in sickle cell disease patients and in vitro. American Society of Hematology 55th Annual Meeting. New Orleans, LA, 2013.
15. Koch K, Leonard C, Bagemihl K, Marks D, Abshire T, Field JJ. An intensive model of care for adults with sickle cell disease that rapidly reduces hospital admissions, readmissions and cost. American Society of Hematology 55th Annual Meeting, New Orleans, LA, 2013. [Oral presentation]
16. Karafin M, Field JJ, Gottschall J, Denomme G. Barriers to using molecularly typed minority red cell donors in support of chronically transfused adult patients with sickle cell disease. American Association of Blood Banks Annual Meeting, Philadelphia, PA, 2014.
17. Karafin M, Koch K, Dargatz J, Field JJ. Chronic red cell transfusion therapy reduces hospitalization and ED admissions for acute pain in patients with sickle cell disease. American Association of Blood Banks Annual Meeting, Philadelphia, PA, 2014. [Oral presentation]
18. Karafin M, Koch K, Rankin A, Nischik D, Field JJ. Serum erythropoietin is associated with hepcidin level in adults with sickle cell disease. American Association of Blood Banks Annual Meeting, Philadelphia, PA, 2014. [Oral presentation]
19. Lindner J, Widlansky M, Wu M, Dargatz J, Harmann L, Belcik T, Neuberger D, Nathan D, Linden J, Field JJ. Contrast-enhanced ultrasound detects differences in microvascular blood flow in adults with sickle cell disease administered regadenoson. American Society of Hematology 56th Annual Meeting, San Francisco, CA, 2014.
20. Majerus E, Ataga D, Vichinsky E, Eaton C, Mazanet R, Nathan D, Field JJ. NKTT120 reduces iNKT cells without dose limiting toxicity in stable adult sickle cell patients in a phase I trial. American Society of Hematology 56th Annual Meeting, San Francisco, CA, 2014.
21. Field JJ, Mehrad B, Burdick M, Shahir K, Nischik D, Simpson P, Strieter R, Rose C. Higher levels of circulating fibrocytes are associated with lower oxygen saturation in adults with sickle cell disease. American Society of Hematology 56th Annual Meeting, San Francisco, CA, 2014.
22. Mazanet R, Schaub R, Scheuplein F, Eaton C, Mashal R, Field JJ. Adult patients with stable sickle cell disease prior to treatment with the iNKT cell depleting antibody NKTT120 have consistent and elevated numbers of activated (CD69+) iNKT cells relative to healthy adult volunteers. American Society of Hematology 56th Annual Meeting, San Francisco, CA, 2014.
23. Wallace C, Mata H, Wandersee N, Scott JP, Brandow A, Field JJ, Karafin M, Hillery C. Children with sickle cell disease on chronic red cell transfusion experience fewer hospitalizations for acute vaso-occlusive episodes irrespective of the indication for transfusion. American Society of Hematology 56th Annual Meeting, San Francisco, CA, 2014.
24. Karafin MS, Irani MS, Puca KE, Baumann Kreuziger L, Field JJ. Blood storage age is an important consideration for chronic red cell transfusion recipients with sickle cell disease (SCD): a national survey of current opinion and practice. American Association of Blood Banks Annual Meeting, Anaheim, CA, 2015.
25. Karafin MS, Carpenter E, Simpson P, Field JJ. Older stored red cell units are frequently used to meet the need of chronically transfused individuals with sickle cell disease. American Association of Blood Banks Annual Meeting, Anaheim, CA, 2015.
26. Field JJ, Majerus EM, Ataga KI, Vichinsky EP, Eaton C, Mazanet R, Nathan DG. NKTT120 safely depletes iNKT cells in stable adult sickle cell patients in a phase I trial. American Society of Hematology 57th Annual Meeting, Orlando, FL, 2015.
27. Singavi A, Chen G, Wandersee N, Hubler C, Brandow A, Simpson P, Li S, Field JJ. Daily pain is associated with alterations in functional connectivity of the brain on fMRI in adults with sickle cell disease. American Society of Hematology 58th Annual Meeting, San Diego, CA, 2016.
28. Lanzkron S, Haywood Jr C, Little J, Field JJ, Shows JR, Segal J, Saheed M, Robertson D, Proudford M, Kincaid A, Burgess L, Green C, Wang H, Seufert R, Brooks J, Griffin B, Piehet A, Frymark S, Varadhan R. Acute care utilization is more common in patients with sickle cell disease who have chronic complications and chronic pain: a preliminary report from the escaped trial. American Society of Hematology 58th Annual Meeting, San Diego, 2016.

29. Lanzkron S, Seufert R, Little J, Field JJ, Shows JR, Haywood Jr C, Saheed M, Varadhan R, Segal J, Wang H, Brooks J, Frymark S, Griffin B, Kincaid A, Burgess L, Robertson D, Proudford M, Green C, Piehet A, Wang S, Huang C. Men with Sickle Cell Disease Show Significant Concerns over Safety While Being Treated for Vaso-Occlusive Crises: Preliminary Observations from the Escaped Trial. American Society of Hematology 59th Annual Meeting, Atlanta, 2017.
30. Sears M, Ewing C, Lanzkron S, Field JJ, Hoppe C, Little J. A Prospective Multi-Centered Registry Is Feasible in Sickle Cell Disease: Globin Regional Network for Data and Discovery (GRNDaD). American Society of Hematology 59th Annual Meeting, Atlanta, 2017.